3,6'- and 1,6'-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation

• Main Authors: Yan-Rou Tsai (Author), Dong Seok Kim (Author), Shih-Chang Hsueh (Author), Kai-Yun Chen (Author), John Chung-Che Wu (Author), Jia-Yi Wang (Author), Yi-Syue Tsou (Author), Inho Hwang (Author), Yukyung Kim (Author), Dayeon Gil (Author), Eui Jung Jo (Author), Baek-Soo Han (Author), David Tweedie (Author), Daniela Lecca (Author), Michael T. Scerba (Author), Warren R. Selman (Author), Barry J. Hoffer (Author), Nigel H. Greig (Author), Yung-Hsiao Chiang (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

(<b>1</b>) <b>Background:</b> An important concomitant of stroke is neuroinflammation. Pomalidomide, a clinically available immunomodulatory imide drug (IMiD) used in cancer therapy, lowers TNF-α generation and thus has potent anti-inflammatory actions. Well-tolerated analogs...